Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer

K. A. Selting; R. Ringold; B. Husbands; P. O. Pithua

doi:10.1111/jvim.13954

Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer

K. A. Selting, R. Ringold, B. Husbands, P. O. Pithua

Veterinary Clinical Sciences

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

BACKGROUND: Serum thymidine kinase type 1 (TK1) and canine C-Reactive Protein (cCRP) might be useful in detecting dogs with cancer. Algorithms combining biomarkers are sometimes more accurate than results of individual tests.

OBJECTIVES: The aim of this study was to compare serum TK1 and cCRP and Neoplasia Index (NI) in healthy and tumor-bearing dogs.

ANIMALS: Client-owned dogs with (n = 253) and without (n = 156) cancer.

METHODS: Retrospective case-control study. Dogs with cancer were identified after submission of samples for commercial assay and case details were retrospectively collected. Healthy dogs (control) were identified through breed groups and health status was confirmed by health questionnaire for a minimum of 6 months. Serum TK1 activity was measured using a quantitative chemiluminescent assay and serum cCRP was measured using a quantitative ELISA assay.

RESULTS: TK1 activity in the cancer (n = 253) and control group (n = 156) were 7.0 μ/L (median, range <0.5 to >100) and 1.8 μ/L (median, range 0.4 to 55.3), respectively (P < .001). cCRP concentrations in the cancer and control group were 6.0 mg/L (median, range <0.5 to >50) and 1.6 mg/L (median, range 0.09 to >50), respectively (P < .001). The NI in the cancer and control group were 6.4 (median, range 0-9.9) and 0.9 (median, range 0-7.6), respectively (P < .001). ROC AUCs of the NI and TK1 for all cancers were greater than 0.8, highest for lymphoma and histiocytic sarcoma.

CONCLUSIONS AND CLINICAL IMPORTANCE: Increased concentrations of TK1 and cCRP, when present in dogs with cancer, might be useful in confirming a diagnosis and monitoring response to treatment.

Original language	English (US)
Pages (from-to)	1159-1166
Number of pages	8
Journal	Journal of veterinary internal medicine
Volume	30
Issue number	4
DOIs	https://doi.org/10.1111/jvim.13954
State	Published - Jul 1 2016

Bibliographical note

Publisher Copyright:
Copyright © 2016 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.

Keywords

Biomarker
Inflammation
Monitoring
Screening

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1111/jvim.13954

OpenUrl availability

Full text

Cite this

@article{1df26eea9508424ba49f0788ed2f8d02,

title = "Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer",

abstract = "BACKGROUND: Serum thymidine kinase type 1 (TK1) and canine C-Reactive Protein (cCRP) might be useful in detecting dogs with cancer. Algorithms combining biomarkers are sometimes more accurate than results of individual tests.OBJECTIVES: The aim of this study was to compare serum TK1 and cCRP and Neoplasia Index (NI) in healthy and tumor-bearing dogs.ANIMALS: Client-owned dogs with (n = 253) and without (n = 156) cancer.METHODS: Retrospective case-control study. Dogs with cancer were identified after submission of samples for commercial assay and case details were retrospectively collected. Healthy dogs (control) were identified through breed groups and health status was confirmed by health questionnaire for a minimum of 6 months. Serum TK1 activity was measured using a quantitative chemiluminescent assay and serum cCRP was measured using a quantitative ELISA assay.RESULTS: TK1 activity in the cancer (n = 253) and control group (n = 156) were 7.0 μ/L (median, range <0.5 to >100) and 1.8 μ/L (median, range 0.4 to 55.3), respectively (P < .001). cCRP concentrations in the cancer and control group were 6.0 mg/L (median, range <0.5 to >50) and 1.6 mg/L (median, range 0.09 to >50), respectively (P < .001). The NI in the cancer and control group were 6.4 (median, range 0-9.9) and 0.9 (median, range 0-7.6), respectively (P < .001). ROC AUCs of the NI and TK1 for all cancers were greater than 0.8, highest for lymphoma and histiocytic sarcoma.CONCLUSIONS AND CLINICAL IMPORTANCE: Increased concentrations of TK1 and cCRP, when present in dogs with cancer, might be useful in confirming a diagnosis and monitoring response to treatment.",

keywords = "Biomarker, Inflammation, Monitoring, Screening",

author = "Selting, {K. A.} and R. Ringold and B. Husbands and Pithua, {P. O.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2016 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.",

year = "2016",

month = jul,

day = "1",

doi = "10.1111/jvim.13954",

language = "English (US)",

volume = "30",

pages = "1159--1166",

journal = "Journal of veterinary internal medicine",

issn = "0891-6640",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer

AU - Selting, K. A.

AU - Ringold, R.

AU - Husbands, B.

AU - Pithua, P. O.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - BACKGROUND: Serum thymidine kinase type 1 (TK1) and canine C-Reactive Protein (cCRP) might be useful in detecting dogs with cancer. Algorithms combining biomarkers are sometimes more accurate than results of individual tests.OBJECTIVES: The aim of this study was to compare serum TK1 and cCRP and Neoplasia Index (NI) in healthy and tumor-bearing dogs.ANIMALS: Client-owned dogs with (n = 253) and without (n = 156) cancer.METHODS: Retrospective case-control study. Dogs with cancer were identified after submission of samples for commercial assay and case details were retrospectively collected. Healthy dogs (control) were identified through breed groups and health status was confirmed by health questionnaire for a minimum of 6 months. Serum TK1 activity was measured using a quantitative chemiluminescent assay and serum cCRP was measured using a quantitative ELISA assay.RESULTS: TK1 activity in the cancer (n = 253) and control group (n = 156) were 7.0 μ/L (median, range <0.5 to >100) and 1.8 μ/L (median, range 0.4 to 55.3), respectively (P < .001). cCRP concentrations in the cancer and control group were 6.0 mg/L (median, range <0.5 to >50) and 1.6 mg/L (median, range 0.09 to >50), respectively (P < .001). The NI in the cancer and control group were 6.4 (median, range 0-9.9) and 0.9 (median, range 0-7.6), respectively (P < .001). ROC AUCs of the NI and TK1 for all cancers were greater than 0.8, highest for lymphoma and histiocytic sarcoma.CONCLUSIONS AND CLINICAL IMPORTANCE: Increased concentrations of TK1 and cCRP, when present in dogs with cancer, might be useful in confirming a diagnosis and monitoring response to treatment.

AB - BACKGROUND: Serum thymidine kinase type 1 (TK1) and canine C-Reactive Protein (cCRP) might be useful in detecting dogs with cancer. Algorithms combining biomarkers are sometimes more accurate than results of individual tests.OBJECTIVES: The aim of this study was to compare serum TK1 and cCRP and Neoplasia Index (NI) in healthy and tumor-bearing dogs.ANIMALS: Client-owned dogs with (n = 253) and without (n = 156) cancer.METHODS: Retrospective case-control study. Dogs with cancer were identified after submission of samples for commercial assay and case details were retrospectively collected. Healthy dogs (control) were identified through breed groups and health status was confirmed by health questionnaire for a minimum of 6 months. Serum TK1 activity was measured using a quantitative chemiluminescent assay and serum cCRP was measured using a quantitative ELISA assay.RESULTS: TK1 activity in the cancer (n = 253) and control group (n = 156) were 7.0 μ/L (median, range <0.5 to >100) and 1.8 μ/L (median, range 0.4 to 55.3), respectively (P < .001). cCRP concentrations in the cancer and control group were 6.0 mg/L (median, range <0.5 to >50) and 1.6 mg/L (median, range 0.09 to >50), respectively (P < .001). The NI in the cancer and control group were 6.4 (median, range 0-9.9) and 0.9 (median, range 0-7.6), respectively (P < .001). ROC AUCs of the NI and TK1 for all cancers were greater than 0.8, highest for lymphoma and histiocytic sarcoma.CONCLUSIONS AND CLINICAL IMPORTANCE: Increased concentrations of TK1 and cCRP, when present in dogs with cancer, might be useful in confirming a diagnosis and monitoring response to treatment.

KW - Biomarker

KW - Inflammation

KW - Monitoring

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=84971212720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971212720&partnerID=8YFLogxK

U2 - 10.1111/jvim.13954

DO - 10.1111/jvim.13954

M3 - Article

C2 - 27214230

AN - SCOPUS:84971212720

SN - 0891-6640

VL - 30

SP - 1159

EP - 1166

JO - Journal of veterinary internal medicine

JF - Journal of veterinary internal medicine

IS - 4

ER -

Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this